Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53MVA Vaccine and Gemcitabine in Recurrent Ovarian Cancer
NCT02275039Phase 1Completed
- Sponsor
- City of Hope
- Start
- Feb 2015
- Primary completion
- Apr 2018
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of p53MVA in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by City of Hope. Started Feb 2015; status: completed.
02
Drugs
p53MVA
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02275039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275039.